Craft

23andMe

Stock Price

$4.9

2024-10-29

Market Capitalization

$169.1 M

2024-08-26

Revenue

$219.6 M

FY, 2024

23andMe Summary

Company Summary

Overview
23andMe Holding (formerly known as VG Acquisition) is a consumer genetics and research company. It aims to help individuals to understand their genetic information through DNA analysis technologies and web-based interactive tools. The company operates through Consumer and Research Services and Therapeutics segments. The Consumer and Research Services business segment comprises personal genome service (PGS), telehealth business, and research services. The Therapeutics segment focuses on the use of genetic insights from the database of genetic and phenotypic information.
Type
Public
Status
Active
Founded
2006
HQ
Sunnyvale, CA, US | view all locations
Website
https://www.23andme.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Anne Wojcicki

    Anne Wojcicki, Co-Founder and Chief Executive Officer

  • Kathy Hibbs

    Kathy Hibbs, Chief Administrative Officer

  • Kenneth Hillan

    Kenneth Hillan, Chief Therapeutics Officer

  • Jeffrey Pollard

    Jeffrey Pollard, Director of Medical Affairs

Operating MetricsView all

Countries

50

Apr, 2020

Customers

10M

Apr, 2020

DNA Kits Sold

10M

Feb, 2020

LocationsView all

2 locations detected

  • Sunnyvale, CA HQ

    United States

    223 N Mathilda Ave

  • South San Francisco, CA

    United States

    349 Oyster Point Blvd

23andMe Financials

Summary Financials

Revenue (Q3, 2025)
$60.3M
Gross profit (Q3, 2025)
$39.8M
Net income (Q3, 2025)
($53.0M)
Cash (Q3, 2025)
$79.4M
EBIT (Q3, 2025)
($35.9M)
Enterprise value
$150.3M

Footer menu